Starling Oncology (STLN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually for stockholders of record as of April 24, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of eight directors is up for vote.
Ratification of BDO as the independent registered public accounting firm for 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Advisory vote on the preferred frequency of future say-on-pay votes is proposed, with the board recommending a 1-year frequency.
Board of directors and corporate governance
Eight nominees for director positions are listed: Brad Hively, Karen Johnson, Mohit Kaushal, Anne McGeorge, Mark Pacala, Mark Stolper, Kimberly Tzoumakas, and Daniel Virnich.
Latest events from Starling Oncology
- Profitable growth, pharmacy-led revenue, and national expansion drive a multi-billion dollar outlook.STLN
Wells Fargo 21st Annual Healthcare Conference - Rapidly scaling oncology VBC platform with strong growth, profitability, and clinical outcomes.STLN
Investor presentation - Achieved 28% revenue growth in 2025 and expects positive Adjusted EBITDA in 2026.STLN
Investor presentation - Q2 2026 saw record revenue, positive adjusted EBITDA, and raised guidance on strong contract growth.STLN
Q2 2026 - Value-based oncology platform posts 28% revenue growth and targets profitability in 2026.STLN
Investor presentation - 41% revenue growth, record pharmacy results, and improved profitability in Q1 2026.STLN
Q1 2026 - Board recommends voting for all proposals, emphasizing governance and executive pay alignment.STLN
Proxy filing - Delegated contracts and dispensary growth drive profitability and expansion through 2028.STLN
25th Annual Needham Virtual Healthcare Conference - Q3 2024 revenue up 21.8% with strong Dispensary growth and new capitation contracts fueling gains.STLN
Q3 2024